Current role of biological agents in colorectal cancer

Journal of the Hong Kong College of Radiologists

Volumn 13, Issue 3 SUPPL., 2010, Pages 3-9

  Cassidy, Jim ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Bevacizumab; Capecitabine; Cetuximab; Colorectal neoplasms

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CEDIRANIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GENE MUTATION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NONHUMAN; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 79952055927     PISSN: 10295097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Centre for Health Protection (CHP). Colorectal cancer. Available at: http://www.chp.gov.hk/en/content/9/25/51.html. Accessed 21 Oct 2010.
2. Law CK, Mang O. Cancer incidence in Hong Kong. Medical Bulletin. 2007;12:18-21.
3. World Health Organization (WHO). Cancer. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 2 Nov 2010.
4. Van Cutsem E, Oliveira J; ESMO Guidelines Working Group. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:S49-50.
5. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985-92.
6. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol. 2002;21:128.
7. Chau I, Cunningham D. Oxaliplatin for colorectal cancer in the United States: better late than never. J Clin Oncol. 2003;21:2049-51.
8. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37. (Pubitemid 41095086)
9. Pelusi J. Capecitabine versus 5-FU in metastatic colorectal cancer: considerations for treatment decision-making. Community Oncol. 2006;3:18-27.
10. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-91. (Pubitemid 41095141)
11. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006-12.
12. Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol. 2009;27(Suppl):S4010.
13. Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO 16968): No impact of age on disease-free survival (DFS). Presented at: American Society of Clinical Oncology Gastrointestinal Symposium (ASCO-GI) 2010; Orlando, Florida.
14. National electronic Library for Medicines (NeLM). NeLM news service: EMEA approves capecitabine combination with oxaliplatin for adjuvant treatment of patients with early colon cancer Available at: http://www.nelm.nhs.uk/en/NeLM- Area/News/2010-March/31/EMEA-approves-capecitabine-combination-with-oxaliplatin- for-adjuvant-treatment-of-patients-with-early-colon-cancer/?query= capecitabine&rank=100. Accessed 21 Oct 2010.
15. National Comprehensive Cancer Network (NCCN). NCCN Colon Cancer Guidelines; 2007.
16. National Cancer Institute (NCI). NCI FactSheet: Targeted Cancer Therapies. Available at: http://www.cancer.gov/cancertopics/factsheet/Therapy/ targeted. Accessed 6 Nov 2010.
17. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117:2051-8. (Pubitemid 47224766)
18. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697-705.
19. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65:4389-400. (Pubitemid 40775678)
20. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin Colorectal Cancer. 2009;8:59-60.
21. AstraZeneca International. RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer. Available at: http://www.astrazeneca.com/media/latest-press-releases/recoentin-horizon?itemId= 8748245. Accessed 6 Nov 2010.
22. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795-803. (Pubitemid 37328914)
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42. (Pubitemid 38702844)
24. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
25. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44. (Pubitemid 46733080)
26. Goldberg RM, Meropol NJ, Tabernero J. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. Gastrointest Cancer Res. 2009;3(5 Supplement 2):S23-7.
27. Cohn A, Bekaii-Saab T, Bendell J, et al. Clinical outcomes of bevacizumab-treated patients with metastatic colorectal cancer: Results from ARIES observational cohort study and confirmation of the BRITE data on bevacizumab beyond progression. Presented at: American Society of Clinical Oncology (ASCO) 2009; Orlando, Florida.
28. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-15. (Pubitemid 351325672)
29. Milano G, Etienne-Grimaldi MC, Dahan L, et al. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol. 2008;19:2033-8.
30. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12.
31. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: Updated data from the OPUS study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2010; Orlando, Florida.
32. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-10. (Pubitemid 24359290)
33. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981-9. (Pubitemid 41430564)
34. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
35. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-8.
36. Erbitux® Prescribing Information. www.packageinserts.bms.com/pi/ pierbitux.pdf.
37. Rougier P, Stroiakovski D, Könne C, et al. Addition of cetuximab to FOLFIRI in first-line metastatic colorectal cancer (mCRC): Updated survival data and influence of KRAS status on outcome in the CRYSTAL study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2009; Orlando, Florida.
38. Garcia-Foncillas J, Diaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transi Oncol. 2010;12:533-42.
39. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-71.
40. Kohne C, Rougier P, Stroh C, et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): A meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO- GI) 2010; Orlando, Florida.
41. Bokemeyer C, Kohne C, Rougier P, et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol. 2010;28(Suppl):S15.
42. Tveit K, Guren T, Glimelius B, et al. Randomized Phase III study of the 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VlI study (NCT00145314), by the NORDIC Colorectal Cancer Biomodulation Group. Ann Oncol. 2010;21(Suppl 8):viii9.
43. Maughan T, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer Suppl. 2009;7:S4.
44. Maughan TS, Adams R, Smith CG, et al. Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: The effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer (ACRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) 2010; Orlando, Florida.
45. Simkens L, Tol J, Koopman M, et al. Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group. Clin Colorectal Cancer. 2008;7:105-9. (Pubitemid 351518771)